Le Lézard
Classified in: Science and technology, Covid-19 virus
Subjects: AWD, CHI, BFA

Innovative Virtual AI Tutor of Spoken English from Buddy.ai Was Declared the Best Education Technology in Latin America by the South Summit 2020 Startup Competition


SAN FRANCISCO, Oct. 12, 2020 /PRNewswire/ -- Buddy.ai has won the South Summit's Education award just two months after its highly anticipated launch in Latin America.

South Summit 2020 Startup Competition is a major event, with 3,800 startups working in Latin America and South Europe competing. Buddy.ai was selected for the prestigious award based on four criteria: innovation, ability to solve education problems at scale, a team of developers, and investment attractiveness.

Educational experts recognize the world-changing potential of virtual teachers as well as the scale of the business opportunity presented by a product like Buddy.ai. Other than the fact that Buddy is always available to learn, Buddy.ai works just like a human tutor - he provides live speaking practice, adapts to the student's learning pace and style, gives them actionable feedback, and acts as an accountability figure to make sure the lessons get done. And kids love studying with their play buddy.

This South Summit award is a clear sign that virtual teacher technology like Buddy.ai, which was until recently considered to be purely sci-fi, is finally taking its place in the sun as an essential part of the educational landscape.

Notably, Buddy the virtual teacher won the South Summit 2020 Startup Competition in Madrid only a couple of months after launching in Latin America and just weeks after reaching the Top-10 of the App Store in the "Kids" category in Mexico and Chile. Today, the Buddy.ai app has over 28,000 paying students. The virtual tutor's popularity is amplified by the severe shortage of qualified teachers, a part of the "new normal" of online learning during the COVID-19 pandemic. Buddy.ai is addressing this challenge not by replacing human teachers, but by automating the mundane 80% of their job, so they can focus on the most critical 20% - time spent with their students. It provides unlimited personalized English practice to the children and empowers teachers to focus on the most important aspects of their job.

It's fair to say that Buddy, the AI inside Buddy.ai's mobile app, is the world's first truly virtual teacher available to the public. Buddy may not be as sophisticated as AI from movies like Her or Iron Man, but Buddy is great at the one job he has - helping kids around the world learn English.

Contact:
Ivan Crewkov, Co-founder and CEO
+1(650)282-1302
[email protected] 

SOURCE Buddy.ai


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: